Use of guanfacine in the treatment of behavioral disorders
AssigneesAmy F. T. Arnsten, Patricia Goldman-Rakic, Robert H. Hunt
InventorsAmy F. T. Arnsten, Patricia S. Goldman-Rakic, Robert H. Hunt
Life of this patent
Estimating the term…
Abstract
Disclosed is a method of treating disorders which have prominent symptoms of behavioral disinhibition (e.g., Attention-Deficit Hyperactivity Disorder, Conduct Disorder, Oppositional Defiant Disorder, Tourette's Syndrome, Lesch-Nyhan Syndrome, or the disinhibitory symptoms accompanying Post-traumatic Stress Disorder or dementia) in a primate with minimal sedative side effects by administering thereto a therapeutically effective amount of guanfacine.
Claims12
A method of treating a behavioral disinhibition in a primate without inducing excessive sedation, comprising
- administering to the primate a behavior inhibiting dose of guanfacine, wherein the dose ranges between 0.01 mg/kg of body weight and 0.86 mg/kg of body weight.
A method of inhibiting a disinhibitory behavior in a primate without inducing excessive sedation, comprising:
- administering to the primate a behavior inhibiting dose of guanfacine, wherein the dose ranges between 0.01 mg/kg of body weight and 0.86 mg/kg of body weight.
Dependencies are inferred from the claim text.